BIOTRICITY INC.
Moat Score — Biotricity Inc.
Total Moat Score
6 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Biotricity's Cardiac AI Cloud platform, trained on over two trillion anonymized heartbeats, represents a genuine proprietary data and AI-model asset that would be costly and time-consuming for a new entrant to replicate. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Improving gross margins (81.5%) and a high recurring-fee revenue mix suggest favorable unit economics are emerging, but the company remains too small to claim a structural cost advantage over larger remote monitoring competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | A high recurring-technology-fee mix (91.2% of revenue) suggests providers value and continue paying for the platform, indicating some pricing durability, though reimbursement dynamics ultimately constrain pricing in this category. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 1 / 5 | Biotricity's diagnostic AI model plausibly improves as more anonymized cardiac data flows through its platform from its provider and patient base, creating a mild data-driven network effect that strengthens with scale. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Healthcare providers who have integrated Biotricity's monitoring workflow and diagnostic reporting into their clinical practice face some workflow-based switching costs, though rival remote cardiac monitoring platforms remain available alternatives. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | At roughly $4 million in quarterly revenue, Biotricity is small relative to larger remote cardiac monitoring competitors and does not yet possess an efficient-scale barrier to entry against better-capitalized rivals. |